Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
SEC Accession No. 0001213900-25-026299
Filing Date
2025-03-31
Accepted
2025-03-31 16:30:03
Documents
7
Period of Report
2025-03-31

Document Format Files

Seq Description Document Type Size
1 REPORT OF FOREIGN PRIVATE ISSUER ea0235929-6k_enlivex.htm 6-K 10885
2 THE AUDITED CONSOLIDATED FINANCIAL STATEMENTS OF ENLIVEX AS OF DECEMBER 31, 2024 ea023592901ex99-1_enlivex.htm EX-99.1 455537
3 CONSENT OF YAREL + PARTNERS ea023592901ex99-2_enlivex.htm EX-99.2 3585
4 GRAPHIC ex99-1_001.jpg GRAPHIC 7808
5 GRAPHIC ex99-2_001.jpg GRAPHIC 4001
6 GRAPHIC ex99-2_002.jpg GRAPHIC 2343
7 GRAPHIC ex99-2_003.jpg GRAPHIC 5771
  Complete submission text file 0001213900-25-026299.txt   499289
Mailing Address 37 DEREH MENACHEM BEGIN ST. 15TH FLOOR TEL AVIV L3 6522042
Business Address 37 DEREH MENACHEM BEGIN ST. 15TH FLOOR TEL AVIV L3 6522042 972 (0) 3 7326616
Enlivex Therapeutics Ltd. (Filer) CIK: 0001596812 (see all company filings)

EIN.: 000000000 | State of Incorp.: L3 | Fiscal Year End: 1231
Type: 6-K | Act: 34 | File No.: 001-36578 | Film No.: 25793731
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)